Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 409306 in Schizophrenia
NCT02281773Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2014
- Primary completion
- May 2016
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial of osoresnontrine in schizophrenia (5 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Change From Baseline in the Composite Score of Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB) at 12 weeks. Started Nov 2014; status: completed.
02
Drugs
osoresnontrine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT02281773.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02281773.